EMA Authorised: Aldurazyme (laronidase) — Sanofi B.V.

View source ↗

Summary

The EMA authorised Aldurazyme (laronidase) for mucopolysaccharidosis type I, with Sanofi B.V. as the marketing authorisation holder (decision date 09/09/2024).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type

Drugs mentioned

• Aldurazyme (Laronidase)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis I. MAH: Sanofi B.V.. Decision date: 09/09/2024